Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 16Carcinoma 5Prostatic Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Vipoma 1Recurrence 1Neuroendocrine Tumors 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Gastrinoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × epothilone B × Clear all
NCT00262990 2020-12-17

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Novartis

Phase 3 Completed
829 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡